Fibrinogen is the principal protein of blood clotting. During coagulation, thrombin cleaves fibrinogen into fibrin monomers that polymerize into a mesh-like scaffold, which factor XIIIa cross-links into a mature clot. The fibrinogen beta chain (FGB)¹¹ fibrinogen beta chain (FGB)
one of three polypeptide chains — alpha, beta, and gamma — that assemble into the fibrinogen hexamer; the beta chain contributes to the central E-domain that controls fibrin polymerization kinetics and fiber thickness plays a critical role in determining the mechanical properties of the resulting clot. rs4220 changes a single amino acid in the mature beta chain — arginine to lysine at position 448 — and this seemingly minor substitution affects both how much fibrinogen circulates and how the resulting fibrin network is structured.

The Mechanism

The p.Arg478Lys substitution (position 448 in the mature processed protein, after removal of the 30-residue signal peptide) replaces arginine — a positively charged amino acid with a long guanidinium side chain — with lysine, which is also positively charged but shorter. The change alters the charge distribution and steric properties of the fibrinogen beta chain in a region that participates in fibrin-fibrin lateral aggregation during clot formation. Studies in African populations found that rs4220 is among the FGB variants whose interaction with total fibrinogen levels significantly influences fibrin clot properties — including fiber thickness, clot density, and susceptibility to fibrinolytic breakdown — independently of fibrinogen concentration alone.

The A allele also associates with modestly elevated plasma fibrinogen levels. Fibrinogen is an acute-phase reactant²² Fibrinogen is an acute-phase reactant
plasma levels rise two- to five-fold during inflammation or infection, making fibrinogen both a structural clotting protein and a sensitive marker of systemic inflammation. Elevated fibrinogen from genetic causes — as distinct from acute inflammation — may alter the fibrin network formed during clotting, producing denser clots with increased resistance to plasmin-mediated dissolution.

The Evidence

A prospective cohort study of 1,294 Chinese participants followed for hypertension development identified rs4220 as a predictor of incident hypertension specifically in men³³ A prospective cohort study of 1,294 Chinese participants followed for hypertension development identified rs4220 as a predictor of incident hypertension specifically in men
Ong et al. 2010 (Thrombosis and Haemostasis): among 178 men who developed hypertension from a normotensive baseline, the A allele conferred OR 1.52 (p=0.022); no significant association was found in women. The A allele was also independently associated with elevated baseline plasma fibrinogen levels (β=0.144, p<0.001), suggesting that the hypertension association is partly mediated through fibrinogen's effects on blood viscosity and endothelial shear stress.

A case-control study of 508 MI patients and 503 healthy controls in Chinese Han adults found the opposite direction of effect for coronary events⁴⁴ A case-control study of 508 MI patients and 503 healthy controls in Chinese Han adults found the opposite direction of effect for coronary events
Lu et al. 2008 (Chinese Medical Journal): K allele (A allele) carriers (KK+RK vs RR) had adjusted OR 0.71 for MI (p=0.023). This apparent paradox — elevated fibrinogen yet reduced MI risk — is consistent with evidence that the structural quality of fibrin clots, not merely circulating fibrinogen levels, determines cardiovascular risk. The Arg→Lys substitution may alter clot architecture in ways that reduce plaque-related arterial thrombosis while separately influencing blood pressure through viscosity effects.

A Mendelian randomization analysis of FGB variants including rs4220 in a large Danish cohort found that fibrinogen-increasing alleles produced a ~7% higher plasma fibrinogen level, but this genetically elevated fibrinogen was not associated with venous thromboembolism risk (PE or DVT)⁵⁵ A Mendelian randomization analysis of FGB variants including rs4220 in a large Danish cohort found that fibrinogen-increasing alleles produced a ~7% higher plasma fibrinogen level, but this genetically elevated fibrinogen was not associated with venous thromboembolism risk (PE or DVT)
Klovaite et al. 2013 (Am J Respir Crit Care Med). This Mendelian randomization finding argues against a causal role of fibrinogen levels in VTE, while leaving open a causal role in blood pressure regulation.

In a cross-sectional study of 480 community-dwelling adults, AA homozygotes at rs4220 showed approximately 12% lower carotid intima-media thickness (IMT) compared to other genotypes (Exp. β = 0.88, significant after adjustment for age, sex, BMI, exercise, and smoking)⁶⁶ In a cross-sectional study of 480 community-dwelling adults, AA homozygotes at rs4220 showed approximately 12% lower carotid intima-media thickness (IMT) compared to other genotypes (Exp. β = 0.88, significant after adjustment for age, sex, BMI, exercise, and smoking)
Wu et al. 2020 (PLoS One), consistent with the Chinese MI study's finding of a protective effect for the minor allele.

Evidence level is moderate: multiple studies across diverse populations with consistent fibrinogen-level effects, but contradictory associations for different cardiovascular endpoints, sex-specificity of the hypertension finding, and limited replication in prospective Western cohorts.

Practical Actions

The primary clinically actionable finding for rs4220 A carriers is the sex-specific association with hypertension development. Men carrying the A allele who have elevated fibrinogen levels should monitor blood pressure and fibrinogen periodically. The evidence does not support major changes in supplementation for heterozygotes; the AA homozygote state may warrant more active monitoring. The mixed evidence on cardiovascular outcomes underscores that fibrinogen level alone is an imperfect risk marker — the structural function of the fibrin network matters independently.

Interactions

rs4220 lies in the same gene as the well-studied promoter variants rs1800787 (FGB -148C>T) and rs1800790 (FGB -455G>A), which independently raise fibrinogen levels. Concurrent elevation of fibrinogen from both coding and regulatory FGB variants would be expected to compound the fibrinogen-level phenotype. The Kotzé et al. 2015 study identified interactions specifically between rs4220 and total fibrinogen levels in determining fibrin clot structure, suggesting that the coding variant modifies how elevated fibrinogen translates into clot architectural changes.

The rs6050 (FGA Thr312Ala) and rs6063 (FGG Gly191Arg) variants in the fibrinogen alpha and gamma chains respectively, when present alongside rs4220, may compound fibrin network dysfunction beyond what any single variant predicts.

TM6SF2 (transmembrane 6 superfamily member 2) is a hepatic protein that facilitates the loading of lipids onto very low-density lipoprotein (VLDL) particles¹¹ very low-density lipoprotein (VLDL) particles
VLDL particles transport triglycerides and cholesterol from the liver to the rest of the body for export from the liver. The E167K variant (a glutamate-to-lysine substitution at position 167) creates one of the most interesting genetic trade-offs in human metabolism: it protects your heart while putting your liver at risk.

The E167K mutation causes the TM6SF2 protein to misfold and degrade rapidly²² TM6SF2 protein to misfold and degrade rapidly
E167K reduces TM6SF2 protein levels by 46% in liver cells, impairing the liver's ability to package and export fat. Triglycerides that should leave the liver via VLDL particles instead accumulate inside liver cells, leading to fatty liver disease. But here's the paradox: those same triglycerides that never make it into your bloodstream mean lower circulating lipids and reduced cardiovascular risk. You're trading liver health for heart health.

The Mechanism

TM6SF2 normally resides in the endoplasmic reticulum and ERGIC (ER-Golgi intermediate compartment)³³ endoplasmic reticulum and ERGIC (ER-Golgi intermediate compartment)
The ERGIC is where VLDL particles receive their lipid cargo before secretion, where it helps load triglycerides and cholesterol esters onto nascent VLDL particles. The E167K substitution disrupts this process at a molecular level: the amino acid change from glutamate (negatively charged) to lysine (positively charged) destabilizes the protein structure, leading to accelerated degradation via the ubiquitin-proteasome pathway.

With reduced TM6SF2 protein, the liver specifically fails to assemble and secrete large, triglyceride-rich VLDL1 particles⁴⁴ large, triglyceride-rich VLDL1 particles
VLDL1-apoB100 production is markedly reduced in E167K homozygotes, while smaller VLDL2 production remains normal. VLDL1-triglyceride production drops by 35% in E167K carriers. The triglycerides that can't be exported accumulate in hepatocytes as lipid droplets—the hallmark of nonalcoholic fatty liver disease (NAFLD).

At the molecular level, E167K also impairs the liver's ability to synthesize polyunsaturated phosphatidylcholines⁵⁵ polyunsaturated phosphatidylcholines
E167K carriers have lower hepatic polyunsaturated phosphatidylcholines despite higher total triglycerides, particularly those containing omega-3 fatty acids. Recent research shows that E167K increases the interaction between TM6SF2 and PNPLA3⁶⁶ increases the interaction between TM6SF2 and PNPLA3
TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis, impairing PNPLA3's normal function of transferring polyunsaturated fatty acids (PUFAs) from triglycerides to phosphatidylcholines. This disrupts membrane lipid composition and exacerbates hepatic steatosis.

The Evidence

The E167K variant was discovered in 2014 through an exome-wide association study⁷⁷ discovered in 2014 through an exome-wide association study
Kozlitina et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nature Genetics, 2014 of the Dallas Heart Study cohort. Carriers had significantly elevated liver fat on MRI and higher ALT levels, but paradoxically lower plasma triglycerides and LDL cholesterol.

A 2015 meta-analysis of 91,937 individuals⁸⁸ 2015 meta-analysis of 91,937 individuals
Pirola et al. The dual and opposite role of the TM6SF2-rs58542926 variant. Hepatology, 2015 confirmed the paradoxical effects: T allele carriers had an odds ratio of 2.13 for NAFLD but showed protection against cardiovascular disease through reduced circulating lipids. The effect size is substantial—among the strongest common genetic risk factors for fatty liver disease.

Subsequent studies have shown that E167K is associated with the full spectrum of NAFLD progression⁹⁹ full spectrum of NAFLD progression
TM6SF2 rs58542926 influences hepatic fibrosis progression. Nature Communications, 2014: simple steatosis, steatohepatitis (NASH), advanced fibrosis, and hepatocellular carcinoma. A 2024 study found that E167K homozygotes have dramatically elevated risks¹⁰¹⁰ E167K homozygotes have dramatically elevated risks
OR 5.38 for steatotic liver disease, OR 5.76 for steatohepatitis, OR 11.22 for hepatocellular carcinoma, making this one of the highest-risk genotypes for liver disease.

A 2020 kinetic study using stable isotope tracers¹¹¹¹ 2020 kinetic study using stable isotope tracers
Effects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism. JCI Insight, 2020 in 10 E167K homozygotes revealed the precise mechanism: VLDL1-apoB100 production was markedly reduced and VLDL1-triglyceride production was 35% lower compared to controls. This impaired VLDL1 secretion explains both the hepatic fat accumulation and the cardiovascular protection.

The cardiovascular protection is real: a 2024 community cohort study¹²¹² 2024 community cohort study
TM6SF2-rs58542926 Genotype Has Opposing Effects on Incidence of Hepatic and Cardiac Events. Clinical Gastroenterology and Hepatology, 2024 found that TT genotype carriers had a 3.16-fold increased risk of liver-related events but a 0.76-fold reduced risk of major adverse cardiovascular events. In most risk groups, the absolute decrease in cardiovascular events exceeded the absolute increase in liver-related events.

Practical Implications

If you carry the T allele, your liver is vulnerable but your heart has a genetic advantage. The key is to support your liver proactively while recognizing that you don't face the same cardiovascular lipid burden as non-carriers.

Diet matters more for you than for most people. Animal studies show that dietary phosphatidylcholine containing C18:3 fatty acids¹³¹³ dietary phosphatidylcholine containing C18:3 fatty acids
Dietary PC containing C18:3 completely abolished liver damage from E167K in high-fat diet-fed mice can completely prevent E167K-induced hepatic steatosis and injury. Choline (found in eggs, liver, and soybeans) is a precursor to phosphatidylcholine, and dietary choline restriction increases liver fat in humans¹⁴¹⁴ dietary choline restriction increases liver fat in humans
Circulating triacylglycerol signatures and insulin sensitivity in NAFLD. Journal of Hepatology, 2015.

Your genotype makes you particularly sensitive to high-fat diets. Studies show that caloric restriction can override the prosteatotic effects¹⁵¹⁵ caloric restriction can override the prosteatotic effects
Reduction of caloric intake might override the prosteatotic effects of PNPLA3 and TM6SF2 variants. PLoS ONE, 2016 of E167K. Weight management is not optional—it's essential liver protection for T allele carriers.

Monitoring is critical. E167K carriers show significantly elevated ALT and AST levels¹⁶¹⁶ significantly elevated ALT and AST levels
Meta-analysis of the influence of TM6SF2 E167K variant on plasma concentration of aminotransferases. Scientific Reports, 2016 even before NAFLD is diagnosed. Regular liver enzyme testing can catch early damage. Liver imaging (ultrasound or MRI) every 2-3 years helps assess steatosis progression before it advances to fibrosis.

The lipid paradox has clinical implications. Your naturally lower LDL and triglycerides mean you may not need aggressive lipid-lowering medications that others require. Discuss your genotype with your physician when considering statin therapy—the risk-benefit calculation is different for E167K carriers. However, don't assume your favorable lipid profile means you're metabolically healthy; your liver may be accumulating fat that never shows up in standard lipid panels.

Interactions

The TM6SF2 E167K variant shows strong additive effects with PNPLA3 I148M¹⁷¹⁷ additive effects with PNPLA3 I148M
The additive effects of the TM6SF2 E167K and PNPLA3 I148M polymorphisms. Oncotarget, 2017. When both variants are present, liver fat accumulation and fibrosis risk increase substantially beyond either variant alone. The 2024 mechanistic study¹⁸¹⁸ 2024 mechanistic study
TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer. Clinical and Molecular Hepatology, 2024 showed that E167K increases the interaction between TM6SF2 and PNPLA3 proteins, impairing PNPLA3's ability to transfer polyunsaturated fatty acids from triglycerides to phosphatidylcholines. This protein-level interaction explains why the two variants compound each other's effects on hepatic steatosis.

Other NAFLD-risk variants also interact with TM6SF2: MBOAT7 rs641738, GCKR rs1260326, and HSD17B13 rs72613567¹⁹¹⁹ MBOAT7 rs641738, GCKR rs1260326, and HSD17B13 rs72613567
Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven NAFLD. Hepatology International, 2021 have been studied in multi-variant genetic risk scores. MBOAT7 primarily affects fibrosis progression, while HSD17B13 appears protective against inflammation. These genes are linked through protein-protein interaction networks²⁰²⁰ protein-protein interaction networks
TM6SF2 co-expressed with GCKR and HSD17B13, PNPLA3 co-expressed with GCKR, suggesting shared lipid metabolism pathways.

An interesting gene-diet interaction has been documented: the protective effect of a "Prudent" dietary pattern²¹²¹ protective effect of a "Prudent" dietary pattern
TM6SF2-rs58542926 modifies the protective effect of a prudent dietary pattern. Nutrients, 2023 rich in unsaturated fatty acids on serum triglycerides is significantly modified by E167K—T allele carriers may not benefit from this dietary pattern the way CC carriers do.

Vitamin D travels through your bloodstream bound to a carrier protein called VDBP¹¹ VDBP
Vitamin D binding protein, also known as group-specific component (GC), carries approximately 85-90% of circulating 25(OH)D and 85% of 1,25(OH)2D in the blood (vitamin D binding protein). Roughly 85-90% of the vitamin D in your blood is bound to VDBP, making it the single largest determinant of how vitamin D is transported to tissues, how long it remains in circulation, and how much is available for cellular uptake. The rs7041 variant in the GC gene changes a single amino acid in this carrier protein, creating isoforms with different binding properties that measurably affect your vitamin D levels.

The Mechanism

The rs7041 variant produces a missense change²² missense change
A missense variant changes one amino acid to another in the protein sequence at position 432 of the VDBP protein: aspartic acid (Asp) in the reference form and glutamic acid (Glu) in the alternate form. Together with a second variant in the same gene (rs4588³³ rs4588
The companion GC variant at codon 436, where Thr defines Gc1 and Lys defines Gc2), rs7041 defines the three major VDBP isoforms that differ in binding affinity and glycosylation:

• Gc1f (rs7041-A + rs4588-C): highest binding affinity for 25(OH)D
• Gc1s (rs7041-C + rs4588-C): intermediate binding affinity
• Gc2 (rs7041-A + rs4588-A): lowest binding affinity

The Gc1f isoform (A allele at rs7041) binds vitamin D metabolites most tightly. This means more total vitamin D is protein-bound and less circulates as free 25(OH)D⁴⁴ free 25(OH)D
The unbound fraction of vitamin D that can enter cells directly without receptor-mediated uptake; represents about 0.03% of total circulating 25(OH)D. Paradoxically, individuals with the highest-affinity carrier (AA genotype) tend to have the lowest levels of free, bioavailable vitamin D despite potentially adequate total levels.

The isoforms also differ in glycosylation patterns that affect conversion to Gc-MAF⁵⁵ Gc-MAF
GC protein-derived macrophage activating factor, an immune modulator produced by enzymatic modification of VDBP that activates macrophages. Gc1 isoforms are more efficiently converted to Gc-MAF than Gc2, with implications for innate immune function.

The Evidence

A landmark GWAS of 4,501 Europeans⁶⁶ landmark GWAS of 4,501 Europeans
Ahn J et al. Genome-wide association study of circulating vitamin D levels. Hum Mol Genet, 2010 identified rs7041 as a genome-wide significant determinant of circulating 25(OH)D concentrations (P = 4.1 x 10^-22). A subsequent GWAS focused on VDBP levels⁷⁷ GWAS focused on VDBP levels
Moy KA et al. Genome-wide association study of circulating vitamin D-binding protein. Am J Clin Nutr, 2014 found even stronger association: mean serum DBP concentrations were 7,335, 5,149, and 3,152 nmol/L for individuals carrying 0, 1, and 2 copies of the minor allele respectively (P = 1.42 x 10^-246).

A study in women across reproductive states⁸⁸ study in women across reproductive states
Ganz AB et al. Vitamin D binding protein rs7041 genotype alters vitamin D metabolism in pregnant women. FASEB J, 2018 found that AA (TT on coding strand) carriers had 25(OH)D levels at 80% of CC (GG) carriers (P = 0.05), but paradoxically had 2.5 times higher free 25(OH)D (P < 0.0001). This reflects lower VDBP concentrations with the A allele, resulting in less total binding but more unbound vitamin D available for cellular uptake.

A supplementation study in 234 vitamin D-deficient adults⁹⁹ supplementation study in 234 vitamin D-deficient adults
Al-Daghri NM et al. Efficacy of vitamin D supplementation according to vitamin D-binding protein polymorphisms. Nutrition, 2019 found that homozygous A allele carriers were 6.2 times more likely to remain deficient after supplementation, and heterozygotes 4.2 times more likely, compared to CC homozygotes (P < 0.001). This makes rs7041 one of the strongest genetic predictors of vitamin D supplementation response.

In a cohort of 414 smokers¹⁰¹⁰ cohort of 414 smokers
Janssens W et al. Vitamin D deficiency is highly prevalent in COPD and correlates with variants in the vitamin D-binding gene. Thorax, 2010, AA homozygotes had a 25% reduction in 25(OH)D levels and an increased risk for COPD (OR 2.11, 95% CI 1.20-3.71, P = 0.009).

Practical Implications

The key insight from rs7041 is the distinction between total and free vitamin D. Standard blood tests measure total 25(OH)D, which is heavily influenced by VDBP levels. If you carry the A allele, your total vitamin D may appear low on standard testing even when your free (bioavailable) vitamin D is adequate. This matters because clinical decisions about supplementation are usually based on total 25(OH)D.

AA carriers should consider testing both total and free 25(OH)D if available, may need higher doses to reach standard target levels on total 25(OH)D, and should take vitamin D3 with fat-containing meals for optimal absorption. Consistent daily dosing (e.g. 2,000-4,000 IU daily) may work better than large intermittent doses for genotypes with altered VDBP kinetics.

Interactions

rs7041 interacts directly with rs4588 in the same gene to determine the three VDBP isoforms (Gc1f, Gc1s, Gc2). The combination of both variants provides more information than either alone. rs7041-A with rs4588-A creates the Gc2 isoform (lowest binding affinity), while rs7041-A with rs4588-C creates Gc1f (highest affinity). This means the same rs7041 genotype can have different functional consequences depending on rs4588 status.

rs7041 also interacts with VDR (rs1544410) and CYP2R1 (rs10741657). If VDBP transport is impaired (rs7041 AA) alongside reduced vitamin D activation (CYP2R1 AA) or reduced receptor sensitivity (VDR TT), the combined effect on vitamin D status is compounded. These multi-gene interactions are addressed in compound implications when all relevant genotypes are present.

Glutathione S-transferase Pi 1 (GSTP1) is one of the most abundant Phase II detoxification enzymes¹¹ Phase II detoxification enzymes
Phase II enzymes conjugate activated toxins with molecules like glutathione, making them water-soluble for excretion via urine or bile in the human body, expressed at particularly high levels in the lungs, skin, oesophagus, and placenta. The enzyme catalyzes the conjugation of reduced glutathione (GSH)²² reduced glutathione (GSH)
A tripeptide (glutamate-cysteine-glycine) that serves as the body's master antioxidant and detoxification cofactor to a wide range of electrophilic compounds -- from environmental pollutants like polycyclic aromatic hydrocarbons and heavy metals to chemotherapy drugs like cisplatin and carboplatin.

The rs1138272 variant causes an alanine-to-valine substitution at position 114 (Ala114Val, also designated c.341C>T) in exon 6 of the GSTP1 gene on chromosome 11q13.2. This is the second of two well-characterized functional polymorphisms in GSTP1, the first being Ile105Val (rs1695)³³ Ile105Val (rs1695)
The more common GSTP1 variant, which has a stronger individual effect on enzyme activity and substrate specificity. Together, these two SNPs define the classical GSTP1 haplotype system: *A (Ile105/Ala114, wild-type), *B (Val105/Ala114), *C (Val105/Val114, lowest activity), and *D (Ile105/Val114).

The Mechanism

The Ala114Val substitution sits near the H-site⁴⁴ H-site
The hydrophobic substrate-binding pocket of GST enzymes, which determines what electrophilic compounds the enzyme can process of the GSTP1 enzyme. A comprehensive functional genomics study⁵⁵ functional genomics study
Moyer AM et al. Glutathione S-transferase P1: gene sequence variation and functional genomic studies. Cancer Res, 2008 expressed all known GSTP1 variant allozymes in COS-1 cells and measured their catalytic activity. The Val114 variant retained approximately 80% of wild-type enzyme activity (79.9 +/- 5.1%, p<0.05). By comparison, the Val105 variant dropped to just 21.8% of wild-type activity. The double variant (Val105/Val114, the *C haplotype) showed 74.1% activity -- suggesting that in the context of an already impaired Val105 enzyme, the Val114 change partially compensates through altered protein folding.

The protein-level explanation involves both reduced immunoreactive protein⁶⁶ immunoreactive protein
The amount of GSTP1 protein detectable by antibodies, which reflects both synthesis rate and protein stability and altered substrate kinetics. The wild-type enzyme (Ile105/Ala114) has a Km of 0.33 mM for the standard substrate CDNB⁷⁷ CDNB
1-chloro-2,4-dinitrobenzene, the standard laboratory substrate used to measure GST enzyme activity, indicating high affinity. Variants at position 105 raise the Km to 1.15 mM, reflecting reduced substrate binding. Position 114 modulates thermal stability and the geometry of the substrate-binding pocket without dramatically altering Km on its own, but it contributes meaningfully when both variants are present.

The Evidence

Cancer susceptibility. A meta-analysis of 43 case-control studies⁸⁸ meta-analysis of 43 case-control studies
Kuang M et al. Comprehensive analysis of the association between the rs1138272 polymorphism of the GSTP1 gene and cancer susceptibility. Front Physiol, 2019 totalling 15,688 cancer cases and 17,143 controls found that the TT genotype increases overall cancer risk (OR 1.45, P = 0.002) under a recessive model. The effect was strongest in Asian populations (TT vs CC: OR 6.51) and African populations (T allele: OR 3.66), where the variant is rare and carriers may face higher relative risk. Among Caucasians, the association was significant for specific cancer sites: head and neck cancer (TT: OR 3.11) and lung cancer (dominant model: OR 1.22).

A South African study of oesophageal cancer⁹⁹ South African study of oesophageal cancer
Li D et al. The 341C/T polymorphism in the GSTP1 gene is associated with increased risk of oesophageal cancer. BMC Genetics, 2010 found the CT genotype carried an OR of 4.98 and the TT genotype an OR of 10.9 compared to wild-type, with risk amplified dramatically by tobacco smoking (OR 7.51) and alcohol consumption (OR 15.3) -- environmental exposures that generate the very electrophilic compounds GSTP1 detoxifies.

Haplotype effects. A Serbian prostate cancer study¹⁰¹⁰ Serbian prostate cancer study
Savic-Radojevic A et al. GSTP1 rs1138272 polymorphism affects prostate cancer risk. Medicina, 2020 found that carriers of the GSTP1*C haplotype (Val105 + Val114, combining both rs1695 and rs1138272 variants) had a 5.46-fold higher risk of prostate cancer compared to those with the *A haplotype. The cumulative effect of multiple GST risk alleles (including GSTM1 and GSTT1 deletions) reached a 12-fold risk increase in individuals carrying all four risk variants.

Enzyme biochemistry. A study of all four GSTP1 allozymes¹¹¹¹ study of all four GSTP1 allozymes
Pal A et al. Variants of glutathione S-transferase Pi 1 exhibit differential enzymatic activity and inhibition by heavy metals. PLoS One, 2012 confirmed that allozymes with Ile105 had superior catalytic efficiency and greater substrate affinity. Heavy metal sensitivity varied by genotype -- the Val105/Ala114 variant was most sensitive to mercury, while Ile105/Val114 was least sensitive, suggesting that the Ala114Val change may paradoxically improve tolerance to certain environmental metals.

Practical Implications

The Ala114Val variant alone reduces GSTP1 activity modestly (~20% reduction). The practical significance scales with environmental exposure: individuals with reduced GSTP1 activity who are also exposed to tobacco smoke, heavy metals, pesticides, or occupational chemicals face a disproportionately higher risk because their conjugation capacity is already diminished. Supporting glutathione status through N-acetylcysteine (the most effective oral glutathione precursor), cruciferous vegetables rich in sulforaphane (which upregulates Phase II enzymes including GSTP1), and reducing unnecessary toxicant exposure are the primary actionable strategies.

For individuals undergoing platinum-based chemotherapy (cisplatin, carboplatin), GSTP1 genotype may influence both drug efficacy and toxicity, since GSTP1 directly conjugates platinum compounds. Reduced GSTP1 activity may increase platinum sensitivity but also increase toxicity risk -- a double-edged sword that oncologists should be aware of.

Interactions

The most important interaction is with rs1695 (GSTP1 Ile105Val). The *C haplotype (Val105 + Val114) represents the lowest-activity form of the enzyme, with substantially greater cancer risk than either variant alone. A compound implication covering the combined GSTP1*C haplotype (rs1695 AG or GG + rs1138272 CT or TT) would be clinically meaningful, as the combined recommendation (aggressive glutathione support, minimizing environmental exposures, oncology awareness) goes beyond what either variant alone warrants.

Beyond GSTP1 itself, other glutathione transferase genes (GSTM1, GSTT1) that can be fully deleted (null genotypes) compound the effect. Individuals with GSTP1 variants plus GSTM1-null and/or GSTT1-null genotypes have cumulative reductions in Phase II detoxification capacity. However, GSTM1 and GSTT1 are copy number variants not typically assessed by 23andMe SNP arrays, so this interaction is noted for awareness rather than actionable in this context.

Your liver and pancreas run largely on a transcription factor called hepatocyte nuclear factor 1-alpha (HNF1A)¹¹ hepatocyte nuclear factor 1-alpha (HNF1A)
HNF1A binds DNA as a homodimer and directly activates dozens of genes involved in glucose metabolism, lipoprotein production, and the acute-phase response; pathogenic HNF1A mutations cause MODY3, the most common monogenic diabetes. The rs1169288 variant introduces an isoleucine-to-leucine substitution at codon 27 (p.Ile27Leu, c.79A>C) — a subtle amino acid swap in HNF1A's dimerization domain that carries measurable metabolic consequences across the full spectrum from common polygenic diabetes risk to modifying the onset age of rare monogenic MODY3.

The Mechanism

Position 27 of HNF1A sits within its N-terminal dimerization domain²² dimerization domain
HNF1A must form a dimer to bind DNA efficiently; the dimerization domain mediates protein-protein contact that stabilizes the transcription complex at target gene promoters. The Leucine-27 substitution (C allele) measurably reduces HNF1A transcriptional activity on target promoters including GLUT2 (glucose transporter 2) and albumin in experimental cell models — a finding replicated across multiple expression systems. Because HNF1A directly activates the CRP promoter, the Leu allele is associated with moderately lower basal C-reactive protein levels. Simultaneously, HNF1A regulates hepatic lipoprotein metabolism, and partial loss of function shifts the lipid phenotype toward higher LDL cholesterol and apolipoprotein B — even though CRP falls. This paradoxical combination (lower inflammation marker, higher LDL) has been replicated in multiple large population studies and is a hallmark of the rs1169288C haplotype.

The Evidence

The largest single-study characterization of this variant's metabolic footprint comes from Reiner et al. 2009³³ Reiner et al. 2009
community-based European-American adults from CARDIA (n=2,890 younger adults) and CHS (n=3,680 older adults); two fully independent replication datasets. The C allele was associated with 0.10–0.15 SD units lower CRP and GGT, but concurrently higher LDL cholesterol, apolipoprotein B, creatinine, and fibrinogen — a profile consistent with partial HNF1A hypofunction in hepatic CRP suppression versus lipoprotein synthesis.

For type 2 diabetes, the weight-dependency finding by Yamada et al. 2014⁴⁴ Yamada et al. 2014
861 Japanese subjects (300 T2D, 561 controls); I27L was an independent determinant of beta-cell function in normal-weight individuals, measured by HOMA-β clarifies the earlier inconsistent literature: I27L increases T2D risk specifically in lean individuals, where genetic beta-cell dysfunction is not masked by obesity-driven insulin resistance. In overweight and obese individuals, the HNF1A signal is overwhelmed by weight-related metabolic noise.

The most clinically striking finding involves MODY3: Bacon et al. 2018⁵⁵ Bacon et al. 2018
meta-analysis of 781 HNF1A-MODY patients from UK and Norwegian national cohorts; stratified by mutation type (protein-truncating vs missense) showed that each Leu-27 allele reduced age at diabetes diagnosis by 1.6 years (95% CI −2.6 to −0.7) in the subset with protein-truncating HNF1A mutations. The biological interpretation is clear: the I27L polymorphism already partially impairs the same transcriptional pathway that pathogenic HNF1A mutations devastate; stacking a mild common variant onto a severe rare variant advances disease onset by years.

An unexpected pharmacogenomics application was reported by Cecchin et al. 2017⁶⁶ Cecchin et al. 2017
two independent cohorts of metastatic colorectal cancer patients treated with FOLFIRI; total n=160 discovery + 82 replication: the rs1169288C allele (Leu-27) was associated with 45% higher irinotecan drug exposure and significantly improved progression-free survival. The mechanism involves HNF1A-driven regulation of ABCC2, an irinotecan efflux transporter — the Leu allele reduces ABCC2 expression, allowing more drug to remain in tumor tissue.

Practical Implications

For most C-allele carriers, the key actionable signal is the LDL elevation. Monitoring fasting LDL alongside standard diabetes screening captures both the lipid and glycemic dimensions of this variant's risk profile. In lean individuals, the diabetes risk is particularly relevant because the variant exerts its effect through beta-cell transcriptional insufficiency, which can be partly compensated by reducing carbohydrate-driven insulin demand.

The lower CRP associated with Leu-27 should not be interpreted as cardiovascular protection — it reflects reduced hepatic acute-phase expression, not reduced vascular inflammation. The LDL elevation tells the more complete cardiometabolic story.

Interactions

The rs1169288 C allele is in strong linkage disequilibrium (r² > 0.8, D' > 0.8) with rs2464196 (HNF1A Ser487Asn)⁷⁷ rs2464196 (HNF1A Ser487Asn)
A second common coding variant at the 3' end of HNF1A at codon 487; S487N may have partially independent effects on HNF1A C-terminal transactivation domain function and with the intronic rs2244608. These variants form a common haplotype with a combined frequency of ~30% in Europeans. Because they travel together, published associations with CRP, LDL, and diabetes risk likely reflect the cumulative effect of the whole haplotype rather than Ile27Leu alone.

For individuals carrying pathogenic HNF1A mutations (MODY3 families), the I27L status modifies diagnosis age — a compound interaction between this common variant and rare HNF1A mutations that is now clinically documented. Genetic counselors and MODY clinics should consider rs1169288 genotyping as a modifier when advising MODY3 families about expected disease trajectory.

The SNCA gene¹¹ SNCA gene
Alpha-synuclein (SNCA) encodes the protein that forms the pathological hallmark of Parkinson's disease — Lewy bodies and Lewy neurites — in dopaminergic neurons of the substantia nigra harbours multiple independent risk variants spread across its genomic structure. rs11931074 sits in the 3′ downstream region of SNCA — within or adjacent to an extended 3′ untranslated region (3′ UTR) that recent research has shown stretches much further than previously appreciated. This position gives the variant direct access to the regulatory machinery that controls SNCA mRNA stability, translation efficiency, and ultimately how much alpha-synuclein protein a cell produces.

rs11931074 has been studied across more published meta-analyses than virtually any other common SNCA variant and emerges in the most recent 2025 systematic review as the single most robust SNCA risk marker — showing consistent, low-heterogeneity associations with Parkinson's disease across all tested genetic models and in both Asian and European populations. Its independence from the 3′-block variant rs356219 (which operates through a different regulatory mechanism in a partially overlapping region) makes it an additive source of risk information at the SNCA locus.

The Mechanism

rs11931074 is located at GRCh38 chromosome 4 position 89,718,364, approximately 5–6 kb downstream of the canonical SNCA gene boundary on the plus strand — placing it within an extended 3′ UTR²² extended 3′ UTR
A 2018 study identified alpha-synuclein transcripts in postmortem human brain samples with a 3′ UTR approximately 1,246 nucleotides longer than the canonical form; rs11931074 falls within this extended region that encompasses risk-associated variants previously considered merely downstream of the gene.

The T risk allele at this position is predicted to alter mRNA stability and translation efficiency³³ mRNA stability and translation efficiency
The 3′ UTR is a key regulatory hub: RNA-binding proteins including ELAVL1 and TIAR bind the SNCA 3′ UTR and modulate both mRNA stabilization and translational activation; variants that disrupt these binding sites shift the equilibrium between degradation and active translation in a direction that increases steady-state SNCA expression. Consistent with this, the TT genotype has been directly associated with significantly higher alpha-synuclein protein levels in human brain tissue — providing functional confirmation of the predicted mechanism.

The downstream consequence mirrors the rs356219 story: chronically elevated alpha-synuclein increases the probability of misfolding, oligomerization, and seeding of the insoluble fibrillar aggregates that destroy dopaminergic neurons in the substantia nigra and trigger the progressive motor and non-motor symptoms of Parkinson's disease.

The Evidence

The largest meta-analysis⁴⁴ The largest meta-analysis
Liu et al. An updated analysis with 45,078 subjects confirms the association between SNCA rs11931074 and Parkinson's disease. Neurological Sciences, 2018 pooled 33 studies involving 15,368 PD patients and 29,710 controls. Every tested genetic model reached significance: allelic OR 1.36 (95% CI 1.31–1.42); heterozygous OR 1.44 (95% CI 1.35–1.55); homozygous TT vs. GG OR 1.87 (95% CI 1.68–2.09); recessive OR 1.58 (95% CI 1.46–1.72). Crucially, significant associations appeared in both Asian and Caucasian subgroups, confirming that the risk signal is not ethnicity-specific.

A 2020 meta-analysis⁵⁵ A 2020 meta-analysis
Du et al. Association between alpha-synuclein (SNCA) rs11931074 variability and susceptibility to Parkinson's disease: an updated meta-analysis of 41,811 patients. Neurological Sciences, 2020 (13,403 cases, 28,408 controls) confirmed these results with allelic OR 1.28 (95% CI 1.12–1.45; p=0.0001) and recessive OR 1.40 (95% CI 1.18–1.68; p=0.0002). The study specifically noted low heterogeneity across studies and no evidence of publication bias — two hallmarks of a genuine, reproducible association rather than an artefact of selective reporting.

The 2025 systematic review and meta-analysis⁶⁶ The 2025 systematic review and meta-analysis
Mohammadi et al. Common SNCA Genetic Variants and Parkinson's Disease Risk. International Journal of Molecular Sciences, 2025 including 27 studies explicitly identified rs11931074 as showing "consistent associations with PD across all models" and confirmed it as the most robust common SNCA PD risk variant — more consistent than rs356219, which showed greater heterogeneity across geographic regions.

Beyond disease susceptibility, rs11931074 shows associations with PD clinical features. A 2015 Chinese cohort study⁷⁷ A 2015 Chinese cohort study
Chen et al. Hyposmia correlates with SNCA variant and non-motor symptoms in Chinese patients with Parkinson's disease. Parkinsonism & Related Disorders, 2015 (218 PD patients) found the TT genotype conferred OR 3.24 (95% CI 1.23–8.51) for hyposmia — reduced sense of smell — a well-recognized early non-motor marker of PD. The same study confirmed TT genotype was associated with significantly higher alpha-synuclein levels in brain tissue (p=0.0082), providing the mechanistic link between genotype and phenotype.

A 2019 resting-state fMRI study⁸⁸ 2019 resting-state fMRI study
SNCA rs11931074 polymorphism correlates with spontaneous brain activity and motor symptoms in Chinese patients with Parkinson's disease. Journal of Neural Transmission, 2019 found that TT carriers showed altered spontaneous brain activity in the right angular gyrus compared to GT/GG carriers, with ALFF values negatively correlated with UPDRS III motor scores — suggesting the variant modulates the neural circuitry underlying motor control in affected patients.

Practical Actions

The functional consequence of rs11931074 T-allele carriage — higher alpha-synuclein expression — is the same biological target as for rs356219, meaning the protective strategies that address elevated SNCA expression apply here too: supporting mitochondrial function against alpha-synuclein-driven complex I dysfunction, promoting autophagy to clear misfolded protein, and reducing environmental exposures that independently upregulate SNCA.

The clinically important addition from rs11931074 research is the hyposmia connection. Loss of smell is one of the earliest detectable markers of Parkinson's pathology, appearing years before motor symptoms. TT carriers who notice a declining sense of smell should discuss this with their doctor as a potential early indicator warranting neurological evaluation — the combination of genotype and symptom substantially elevates clinical concern.

Because T allele frequency differs dramatically between populations (about 7% in Europeans versus 53% in East Asians), the genotype interpretation varies substantially by ancestry: TT homozygosity is rare in Europeans (about 1%) but relatively common in East Asians (about 28%), meaning the recessive risk signal has very different population-level impact.

Interactions

rs11931074 and rs356219 are both located in the 3′ region of the SNCA locus but are in different linkage disequilibrium blocks and likely act through partially distinct regulatory mechanisms — rs356219 primarily by altering SNCA transcription, rs11931074 by affecting mRNA stability/translation in the extended 3′ UTR. Independent carriage of risk alleles at both loci may compound alpha-synuclein overproduction through additive regulatory effects, though no single study has formally quantified the joint genotype effect.

rs356182, an intronic SNCA variant affecting neuronal differentiation, represents a third independent risk signal at the SNCA locus. Carriers of risk alleles at rs11931074, rs356219, and rs356182 simultaneously may face substantially elevated cumulative PD susceptibility through three distinct mechanisms — disease risk, elevated expression, and impaired neuronal differentiation — though this triple-carrier scenario has not been formally studied.

The ZMYM4 gene encodes a zinc finger MYM-type containing protein¹¹ zinc finger MYM-type containing protein
a family of chromatin-associated transcription factors that use zinc-coordinated protein domains to regulate gene expression by modifying how tightly DNA is wrapped around histone proteins located on chromosome 1p32. It is expressed broadly across tissues and has emerging roles in fat distribution, immune cell regulation, and developmental gene programs. The rs12094543 variant is an intronic tag SNP within ZMYM4 — it does not alter the protein directly but may influence how and when ZMYM4 is expressed by tagging a regulatory haplotype across the gene body.

The Mechanism

rs12094543 sits at chr1:35,351,102 (GRCh38), approximately 24 kb upstream of rs559986 — the GWAS-significant variant in the same gene associated with waist-hip ratio — and 51 kb upstream of rs113408476, the indel associated with BMI-adjusted waist circumference and A Body Shape Index. All three variants are intronic to ZMYM4, suggesting they tag a common regulatory haplotype.

ZMYM4 encodes a B-MYB binding protein²² ZMYM4 encodes a B-MYB binding protein
B-MYB is a transcription factor that controls cell cycle progression, proliferation, and differentiation in many tissues including adipose and hematopoietic cells. ZMYM4 is highly SUMOylated³³ SUMOylated
SUMOylation is a post-translational modification that changes where a protein goes in the cell and how it interacts with DNA; it often marks chromatin regulatory proteins, and its interaction with B-MYB strengthens after DNA damage, suggesting a role in transcriptional stress responses that could affect adipocyte differentiation or immune cell maturation under metabolic challenge.

The Evidence

Fat distribution: Two large body-composition GWAS have implicated the ZMYM4 locus. Kichaev et al. (2019)⁴⁴ Kichaev et al. (2019)
FINDOR GWAS of 27 UK Biobank traits, N≈416,000 identified rs559986 in ZMYM4 at genome-wide significance for waist-hip ratio, a marker of central adiposity independent of overall weight. Separately, Christakoudi et al. (2021)⁵⁵ Christakoudi et al. (2021)
GWAS of allometric body-shape indices, N=406,697 UK Biobank participants associated ZMYM4 (rs113408476) with BMI-adjusted waist circumference (p~2×10⁻⁸) and A Body Shape Index (ABSI), a validated marker of visceral fat burden. The ABSI association is notable because it captures waist-to-height risk beyond BMI — a better predictor of cardiometabolic disease than either measure alone.

Rare variant obesity burden: Marenne et al. (2020)⁶⁶ Marenne et al. (2020)
exome sequencing in 2,737 severely obese children vs 6,704 controls, Cell Metabolism identified ZMYM4 among three genes carrying an excess burden of very rare predicted- deleterious variants in cases. This is distinct from the common-variant GWAS signals — it suggests that, beyond the population-frequency tag SNPs, rare loss-of-function variants in ZMYM4 may individually cause severe early-onset obesity through disruption of the transcriptional programs that control fat cell development.

Immune and monocyte regulation: Astle et al. (2016)⁷⁷ Astle et al. (2016)
173,480 participants, 36 blood cell traits, Cell associated the ZMYM4 region (rs11581846) with monocyte percentage of white cells at p=1×10⁻⁹. Elevated monocyte percentage is a marker of chronic low-grade inflammation — the same inflammatory state that underlies visceral fat accumulation and metabolic syndrome. A large allergy GWAS (N=360,838)⁸⁸ large allergy GWAS (N=360,838)
Ferreira et al. 2017, Nature Genetics also identified a ZMYM4- region variant among 136 risk loci for asthma, hay fever, and eczema, implying ZMYM4 sits at an intersection of metabolic and immune gene regulation.

The rs12094543 G allele is uncommon in European populations (~2%) but reaches ~41% in East Asian populations — one of the sharpest allele-frequency gradients at this locus — suggesting meaningful evolutionary differentiation that has not yet been mechanistically explained.

Practical Implications

rs12094543 should be read as a genomic signal pointing to ZMYM4's role in fat distribution, not as a direct functional variant. Individuals carrying the G allele (AG or GG) have a genomic profile consistent with increased central fat accumulation tendency, independent of total body weight. Waist circumference and waist-to-hip ratio are the most actionable proxies: when these diverge from weight-based BMI predictions, the ZMYM4 signal may be part of the explanation.

The co-occurrence of fat-distribution and immune associations at this locus is biologically coherent: visceral adipose tissue is metabolically active immune tissue. Elevated monocyte infiltration into visceral fat depots is an early event in insulin resistance, and chromatin regulators like ZMYM4 may coordinate both the adipogenic differentiation program and the innate immune tone of adipose tissue.

Interactions

rs559986 and rs113408476 (ZMYM4 intronic, same gene): These are the GWAS- significant body-shape variants in ZMYM4, both intronic and located within ~50 kb of rs12094543. They likely tag an overlapping regulatory haplotype. If multiple ZMYM4 intronic variants are present together, they may represent a high-risk haplotype for central adiposity rather than independent signals — their combined effect has not been formally tested.

rs11581846 (ZMYM4 region, monocyte percentage and telomere length): This same ZMYM4-region variant has been independently associated with both monocyte immune regulation and telomere length. The convergence of adiposity, immunity, and cellular aging signals at the ZMYM4 locus is consistent with a chromatin regulator that coordinates stress-responsive transcriptional programs across multiple tissue types.

The interleukin-6 receptor sits at one of the most versatile crossroads in human immunology. IL-6 is the cytokine that bridges innate and adaptive immunity, drives the acute-phase response (including C-reactive protein production), and modulates the balance between Th1-driven autoimmune inflammation and Th2-driven allergic disease. rs12133641 is an intronic variant¹¹ intronic variant
Deep intronic variants (>100 bp from any exon) can act as cis-regulatory elements, affecting transcription factor binding, alternative splicing enhancers, or gene expression levels without changing the protein sequence itself located 1,226 bp downstream of an exon boundary in IL6R (c.1160+1226A>G), and it tags a regulatory haplotype with a striking bidirectional disease association: the G allele reduces systemic IL-6 signaling — lowering CRP and cardiovascular inflammation risk — while simultaneously elevating risk for atopic dermatitis and other Th2-mediated allergic conditions.

The Mechanism

IL6R encodes the membrane-bound alpha subunit of the IL-6 receptor²² IL-6 receptor
IL-6 signals through a two-component complex: IL6Rα (CD126, encoded by IL6R) binds IL-6 with low affinity, then recruits gp130 (IL6ST) to form the high-affinity signaling complex that activates JAK1/STAT3 pathways. A soluble form of IL6Rα (sIL-6R) is shed from the cell surface by ADAM10 and ADAM17 proteases; sIL-6R enables IL-6 trans-signaling³³ trans-signaling
Trans-signaling allows IL-6 to activate cells that do not express membrane-bound IL6R, dramatically broadening IL-6's reach to endothelial cells, neurons, and other non-immune cell types on cells that lack membrane IL6R. rs12133641 lies in a deep intronic regulatory region and is in partial linkage disequilibrium with the coding variant rs2228145 (Asp358Ala, c.1073A>C), which reduces IL6R ectodomain shedding and lowers circulating sIL-6R levels. The intronic rs12133641 likely contributes independently to regulatory control of IL6R expression or alternative splicing.

The apparent paradox — reduced IL-6 signaling causing both cardiovascular protection and atopic risk — reflects IL-6's dual role in immune homeostasis. High systemic IL-6 signaling drives Th17 cell differentiation and pro-inflammatory CRP production (bad for heart disease); but IL-6 also suppresses Th2-type eosinophilic inflammation by promoting regulatory immune states. When IL6R variants dampen this suppressive arm, Th2 skewing and IgE-mediated atopic responses may increase.

The Evidence

The atopic dermatitis association was established in a large multi-ancestry GWAS meta-analysis⁴⁴ large multi-ancestry GWAS meta-analysis
Budu-Aggrey et al., Nature Communications 2023; combining European, East Asian, Latin American, and African ancestry datasets with over 800,000 total participants published in Nature Communications (2023, n > 800,000 combined). The G allele was associated with increased AD risk at genome-wide significance (OR ~1.04, p=3×10⁻⁴⁵), an effect that is modest per-allele but highly replicated and consistent across ancestries.

The complementary cardiovascular signals confirm the variant's impact on systemic IL-6 tone. In CAD GWAS data⁵⁵ CAD GWAS data
Hartiala et al. and CARDIoGRAMplusC4D consortium, combining 547,261 participants, the A allele (not G) associated with coronary artery disease risk (p=3×10⁻¹¹) — meaning the G allele is cardiovascular-protective. The most mechanistically direct signal is the CRP association⁶⁶ CRP association
From large-scale CRP GWAS; the G allele consistently lowers CRP across multiple independent studies and populations: the G allele is one of the strongest CRP-reducing variants in the genome (β -0.116 log-units, p=4×10⁻⁴⁷). This confirms that rs12133641 genuinely modifies IL-6 trans-signaling output, not merely tags it.

In skin-specific immune responses, GWAS of mosquito bite reactions⁷⁷ GWAS of mosquito bite reactions
Mitchell et al., PLOS Genetics 2017; 84,724 participants for bite size, 69,057 for itch intensity found the G allele associated with reduced itch intensity (β -0.021, p=9×10⁻⁹) and larger bite size (β +0.028, p=2×10⁻⁷) — consistent with a blunted IL-6-mediated acute inflammatory response to insect antigen, with compensatory Th2-driven wheal formation dominating instead.

Practical Implications

For GG homozygotes, the elevated atopic dermatitis risk is meaningful but modest on an absolute scale. AD affects ~15-20% of children and ~5-10% of adults at baseline; an OR of ~1.04 per allele translates to ~8% higher risk for GG versus AA, not a dramatic increase. The more actionable implication is recognizing the IL-6 signaling context when managing skin inflammation: GG carriers may respond differently to IL-6 pathway-targeting treatments, and the lower basal CRP may obscure inflammatory activity that would otherwise appear on standard inflammatory markers.

For AG heterozygotes — the most common genotype — the modest atopic risk elevation warrants awareness of AD triggers but not targeted intervention beyond standard skincare approaches specific to genetic barrier vulnerability.

Carriers of the G allele who are prescribed IL-6 receptor blockers (tocilizumab, sarilumab) for rheumatoid arthritis, giant cell arteritis, or cytokine release syndrome should be aware that rs12133641 status may influence baseline IL6R expression levels, potentially modifying therapeutic response magnitude.

Interactions

The coding variant rs2228145 (Asp358Ala, 1,313 bp upstream of rs12133641) is the most studied functional variant in IL6R and reduces IL6R ectodomain shedding. rs2228145 is the primary Mendelian randomization instrument for IL-6 signaling studies and has been used to model the effects of tocilizumab pharmacologically. rs12133641 and rs2228145 lie in the same gene and likely tag overlapping but not identical regulatory signals; the complete IL6R haplotype structure including both variants gives the most accurate representation of an individual's IL-6 receptor biology.

rs4129267 is another intronic IL6R variant at chr1:154,453,788 with similar population frequencies (~39% T allele in Europeans) that has been associated with CRP levels, asthma, and cardiovascular phenotypes — it may be in partial LD with rs12133641 and represent the same functional haplotype from a different tag position.

Every cell in your body faces a fundamental challenge: how to safely remove excess cholesterol before it can accumulate and trigger damage. The solution is a large membrane pump called ABCA1¹¹ ABCA1
ATP-binding cassette transporter A1 — a 220 kDa membrane protein that exports cholesterol and phospholipids from cells to form nascent HDL particles. This protein is the master regulator of the first step in reverse cholesterol transport, and variation in the ABCA1 gene substantially shapes an individual's HDL cholesterol level and cardiovascular risk trajectory.

rs12686004 is a variant located deep within an intron of ABCA1 (transcript position c.67-1950, approximately 1,950 base pairs upstream of exon 2 in the reference sequence). It sits within a gene that spans 149 kb across chromosome 9q31.1, containing 50 exons and 49 introns — a large genomic territory with multiple regulatory elements controlling when and how much ABCA1 protein each tissue makes.

The Mechanism

Because rs12686004 lies in a non-coding intronic region, it does not change the ABCA1 protein sequence directly. Its biological impact is most likely regulatory — either altering enhancer activity within the intron, modifying pre-mRNA splicing efficiency, or tagging a nearby functional variant through linkage disequilibrium. This pattern is well-established in ABCA1: two other independent intronic variants, rs2575875 (intron 2) and rs3847301 (intron 3)²² rs2575875 (intron 2) and rs3847301 (intron 3)
Howard et al. demonstrated that both SNPs function as allele-specific enhancers that physically loop back to contact the ABCA1 promoter via chromatin remodeling. PLoS One, 2019, have been shown to act as allele-specific enhancers that physically interact with the ABCA1 promoter through chromatin looping, with genome-wide significant effects on HDL cholesterol (p = 1×10⁻¹⁰ to 9×10⁻¹³).

ABCA1 expression is regulated at multiple levels. The liver X receptor (LXR) — activated by oxysterols when intracellular cholesterol rises — drives ABCA1 transcription through a response element in the proximal promoter. Intron 1 contains an LXR response element that is critical for dietary fat-responsive upregulation in animal models. Intronic variants that alter enhancer activity or splicing can shift the set-point of this response, changing how much ABCA1 protein is produced when cholesterol loads increase.

The Evidence

The most direct evidence for the importance of ABCA1 intronic regulation on HDL comes from two independent signals within the gene itself. Howard et al. (2019) demonstrated that rs2575875 and rs3847301 each independently associate with HDL at genome-wide significance and function as allele-specific enhancers, with the active allele at rs2575875 creating a STAT3 binding site that drives ABCA1 transcription.

Delgado-Lista et al.³³ Delgado-Lista et al.
Delgado-Lista et al. ABCA1 gene variants regulate postprandial lipid metabolism in healthy men. Arterioscler Thromb Vasc Biol, 2010 showed in 88 healthy men that carriers of the major allele at ABCA1 intronic variants (rs2575875/rs4149272) had significantly higher fasting and postprandial apoA1, lower postprandial triglycerides, and a better apoA1/apoB ratio compared to minor allele carriers — demonstrating that intronic ABCA1 variation functionally shapes lipid metabolism after fat intake.

rs12686004 itself is cited in studies examining ABCA1 genetic variation in the context of cholesterol homeostasis and Alzheimer's disease⁴⁴ Alzheimer's disease
Koldamova et al. Role of ABCA1 in Alzheimer's disease and neurodegeneration. Biochim Biophys Acta, 2010. ABCA1 controls brain cholesterol efflux and apoE lipidation, and the LXR–ABCA1–APOE regulatory axis is considered a therapeutic target in neurodegeneration. The A allele's population frequency pattern — approximately 12% in Europeans but only 3% in African populations and approximately 21% in East Asians — suggests population-specific allelic history consistent with ancient demographic events rather than selection for a deleterious variant.

The evidence level for rs12686004 specifically is emerging: it appears in population-scale databases as an ABCA1 intron variant and has been cited in mechanistic studies of the gene, but a definitive effect size for HDL modulation from this variant alone has not been published in a primary association study. The broader framework of ABCA1 intronic regulation is well-established; this variant is a less-characterized member of that class.

Practical Actions

For A allele carriers, the modifiable lever is dietary fat composition and strategies that directly support cholesterol efflux. Because ABCA1 is transcriptionally activated by LXR when intracellular cholesterol accumulates, ensuring adequate dietary cholesterol efflux support (via omega-3 fatty acids and niacin-rich foods that raise HDL) can partially compensate for any intrinsic reduction in ABCA1 regulatory response. Monitoring fasting HDL and triglycerides provides the most direct readout of ABCA1 efflux capacity in practice.

GG homozygotes — carrying the common reference allele — need not take special steps, but awareness of ABCA1's diet-sensitive regulation is relevant for anyone making long-term cardiovascular risk decisions.

Interactions

ABCA1 function is intimately connected to the downstream HDL lifecycle. ABCA1's lipid-export product — nascent HDL — is immediately esterified by LCAT (rs4420638 region) and ultimately cleared by SR-BI receptors in the liver (SCARB1 variants). Variants in APOA1 (the structural protein of HDL) and CETP (the cholesteryl ester transfer protein) further modulate how HDL particles are remodeled downstream of ABCA1's initial efflux step. The APOE genotype (rs429358, rs7412) also interacts with ABCA1 activity in the brain, where APOE isoform affects how well ABCA1-derived cholesterol is recycled for neuronal membrane maintenance.

When your body encounters a viral infection in the liver or airways, it deploys type III interferons¹¹ type III interferons
a family of antiviral signalling proteins that activate the JAK-STAT pathway and interferon-stimulated genes in epithelial and hepatocyte cells as a first line of defence. The IFNL4 gene on chromosome 19q13.2 encodes interferon lambda-4²² interferon lambda-4
one of four interferon lambda proteins (IFNL1–4) that restrict viral replication at mucosal and hepatic barriers, but only in people who carry the T allele at rs12979860. Carriers of the CC genotype produce no functional IFN-λ4 protein at all — their IFNL4 gene is silenced — and paradoxically, this silencing is protective against hepatitis C.

rs12979860 was originally attributed to the nearby IL28B (IFNL3) gene in the landmark 2009 GWAS studies. The discovery in 2013 that the variant actually lies in intron 1 of a newly identified gene, IFNL4, resolved the biological mystery of how an intronic change could exert such profound effects on viral clearance.

The Mechanism

The rs12979860 C>T variant is in strong linkage disequilibrium³³ linkage disequilibrium
non-random co-inheritance of nearby variants with a dinucleotide frameshift variant (ss469415590 TT/ΔG) that either creates or destroys IFNL4 as a functional gene. The T allele at rs12979860 tags the ΔG allele, which generates a functional IFNL4-encoded protein with genuine antiviral activity. The C allele tags the TT allele, which is a loss-of-function that silences IFNL4 entirely.

The apparent paradox — a functional interferon protein impairing viral clearance — is explained by recent mechanistic work. IFN-λ4 is largely retained in the endoplasmic reticulum⁴⁴ IFN-λ4 is largely retained in the endoplasmic reticulum
it fails to be secreted efficiently rather than being released to activate neighbouring cells. Instead, ER-retained IFN-λ4 induces ER stress, and ER-stressed hepatocytes are substantially weaker activators of HCV-specific CD8+ T cells, crippling the adaptive immune response needed to eradicate the virus. Additionally, chronic IFN-λ4 signalling causes pre-activation of interferon-stimulated genes (ISGs) that desensitises hepatocytes to exogenous interferon treatment — explaining both natural and treatment-related impairment.

The Evidence

The 2009 GWAS studies identified rs12979860 as the strongest host genetic predictor of HCV treatment response⁵⁵ strongest host genetic predictor of HCV treatment response
measured as sustained virologic response, SVR, meaning undetectable virus 12–24 weeks after completing therapy, with an odds ratio of approximately 5.8 for SVR in European patients carrying CC versus non-CC (TT/CT) genotypes. In a Japanese cohort, SVR rates were 76.9% in CC, 56.4% in CT, and 12.5% in TT patients⁶⁶ 76.9% in CC, 56.4% in CT, and 12.5% in TT patients receiving peginterferon/ribavirin.

For spontaneous viral clearance (never needing treatment at all), a meta-analysis of 17 studies⁷⁷ meta-analysis of 17 studies found rs12979860 CC confers OR 2.98 (95% CI 2.53–3.50) for HCV elimination without treatment versus CT or TT genotypes. The effect is stronger in Caucasian and African populations than in Asians, where the favourable C allele is near-universal (East Asian T allele frequency ~0.04).

Beyond HCV, the T allele has been associated with impaired viral defences more broadly. A Spanish study found the T allele was overrepresented in COVID-19 patients⁸⁸ the T allele was overrepresented in COVID-19 patients relative to the general population (36.2% vs 26.4%; OR 0.63 for the protective C allele, p=6.4×10⁻⁴). The variant's role in hepatitis B clearance is debated — some studies show the CC genotype predicts HBsAg seroclearance in interferon-treated HBeAg-negative patients, while others find no effect on untreated HBV natural history.

With modern direct-acting antiviral (DAA) regimens for HCV, the IFNL4 variant retains clinical relevance. In the pivotal NEUTRINO trial of sofosbuvir-based therapy, SVR12 was 99% in CC versus 87% in non-CC patients⁹⁹ SVR12 was 99% in CC versus 87% in non-CC patients, and the IFNL4-ΔG genotype is specifically associated with slower early viral decay kinetics even with DAA treatment, influencing whether shorter (8-week) treatment courses can be used safely.

The variant is also an aetiology-independent predictor of liver fibrosis: in a cohort of 4,172 patients with diverse liver diseases¹⁰¹⁰ 4,172 patients with diverse liver diseases — including NAFLD — those with non-CC genotypes (carrying the T/ΔG allele) showed greater hepatic inflammation and fibrosis, confirming IFNL4 signalling promotes liver inflammation beyond viral contexts.

Practical Actions

People with CT or TT genotypes who have ever been exposed to hepatitis C or are at risk should discuss screening and, if infected, the implications for treatment duration with their doctor. While DAA therapy achieves high cure rates even with unfavourable genotypes, the IFNL4 genotype affects how quickly the virus clears and whether shorter treatment protocols are suitable.

For TT carriers who were treated with older peginterferon-based regimens and failed — this failure was largely biologically predetermined, and modern DAA regimens offer a much better chance of cure.

The broader implication for viral immunity (COVID-19, other respiratory viruses) is emerging but suggests that CT and TT carriers have a subtly impaired first-line antiviral response at hepatic and mucosal surfaces. Prioritising vaccination against preventable infections is a rational response.

Interactions

rs12979860 is in strong linkage disequilibrium with rs8099917¹¹¹¹ rs8099917
another IFNL locus variant frequently used for HCV pharmacogenomics testing, r²=0.43–0.65 depending on population and with rs12980275¹²¹² rs12980275
third IFNL3 region variant, r²=0.68–1.0 with rs12979860. Commercial HCV pharmacogenomics panels often report all three; rs12979860 is generally considered the most predictive. The variants should not be summed as independent effects — they tag the same underlying IFNL4 functional state.